Speciality: Oncology
Description:
A warm welcome to all the medical professionals in this exciting learning session on managing Ph negative Acute lymphoblastic leukemia in adults.
Acute Lymphoblastic Leukemia (ALL) is a cancer of the blood and bone marrow that progresses rapidly without treatment. It can reoccur after being in remission from previous treatment. It has been noted that refractory ALL did not respond to treatment indicating the previous treatments did not kill enough leukemia cells (blasts) to reach complete remission.
Ph-positive ALL is a special type of ALL in which a genetic mutation is observed in the Philadelphia chromosome. In the case of Ph-negative ALL, genetic disparities are also observed and most importantly in Ph neg ALL there is a disproportionate survival rate among the patients.
Managing Ph neg ALL often becomes difficult, however, the procedures of management of Philadelphia chromosome (Ph)–negative acute lymphoblastic leukemia (ALL) have changed dramatically in recent years leading to a positive vibe for the situation.
Therefore, have overall knowledge regarding the management of Ph negative ALL. Listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
A Win for Molecularly Guided Therapy for Cancer of Unknown Primary
2.
Dual-action mRNA vaccine takes aim at aggressive skin cancer
3.
In early dementia, SSRIs enhance cognition and major depression.
4.
Study indicates that exercise can help colon cancer survivors live as long as matched individuals
5.
Patients face high out-of-pocket costs after incident cancer diagnosis
1.
Unlocking the Potential of Ferrotonia: A New Way to Harness Magnetic Energy
2.
Understanding Acute Myeloid Leukemia (AML) and Its Survival Rates
3.
Unraveling the Mysteries of Lymphoma: A Journey into the Unknown
4.
Interpreting Iron Studies: What Your Blood Results Really Mean
5.
Understanding Waldenstrom Macroglobulinemia - A Comprehensive Guide
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
The Landscape of First-Line Treatment for Urothelial Carcinoma- Further Discussion
2.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
3.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
4.
Navigating the Complexities of Ph Negative ALL - Part IX
5.
Efficient Management of First line ALK-rearranged NSCLC - Part VI
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation